Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse.
Carolina RoselliMengyao YuVictor NauffalAdrien GeorgesQiong YangKatie LoveLu-Chen WangFrancesca N DellingSvetlana R MauryaMaren SchrölkampJacob Tfelt HansenAlbert HagègeXavier JeunemaitreStephanie DebettePhillippe AmouyelWyliena GuanJochen Daniel MuehlschlegelSimon C BodySvati H ShahZainab SamadSergiy KyryachenkoCarol HaynesMichiel RienstraThierry Le TourneauVincent ProbstRonan RousselInez J Wijdh-Den HamerJoylene E SilandKirk U KnowltonJean-Jacques SchottRobert A LevineEmelia J BenjaminRamachandran S VasanBenjamin D HorneJoseph B MuhlesteinGiovanni BenfariBenjamin A EssayaghAndrea NataleSanghamitra MohantyChintan TrivediMoore B ShoemakerZachary T YonedaQuinn S WellsMichael T BakerEric H Farber-EgerHector I MichelenaAlicia LundbyRussell A NorrisSusan A SlaugenhauptChristian DinaSteven A LubitzNabila Bouatia-NajiPatrick T EllinorDavid J MilanPublished in: European heart journal (2022)
We identified 14 genetic loci that are associated with MVP. Multiple analyses identified candidate genes including two transforming growth factor-β signalling molecules and spectrin β. We present the first PRS for MVP that could eventually aid risk stratification of patients for MVP screening in a clinical setting. These findings advance our understanding of this common valvular heart disease and may reveal novel therapeutic targets for intervention.
Keyphrases
- genome wide association study
- genome wide
- transforming growth factor
- mitral valve
- end stage renal disease
- randomized controlled trial
- epithelial mesenchymal transition
- dna methylation
- newly diagnosed
- chronic kidney disease
- ejection fraction
- copy number
- atrial fibrillation
- peritoneal dialysis
- prognostic factors
- gene expression
- patient reported outcomes
- left atrial